In the US, Neupogen (filgrastim systemic) is a member of the drug class colony stimulating factors and is used to treat Aplastic Anemia, Bone Marrow Transplantation, Myelodysplastic Syndrome, Neutropenia, Neutropenia Associated with AIDS or Zidovudine, Neutropenia Associated with Chemotherapy, Peripheral Progenitor Cell Transplantation and Sepsis.
US matches:
- Neupogen
- Neupogen SingleJect
UK matches:
- Neupogen Singleject Syringes
- Neupogen Vials
- Neupogen 30 MU (0.3 mg/ml) and 48 MU (0.3 mg/ml). Solution for injection (SPC)
- Neupogen Singleject 30 MU (0.6 mg/ml) (SPC)
- Neupogen Singleject 48 MU (0.96 mg/ml) (SPC)
Ingredient matches for Neupogen
Filgrastim
Filgrastim is reported as an ingredient of Neupogen in the following countries:
- Algeria
- Argentina
- Aruba
- Australia
- Austria
- Azerbaijan
- Bahrain
- Bangladesh
- Belarus
- Belgium
- Bolivia
- Bosnia & Herzegowina
- Botswana
- Brazil
- Canada
- Chile
- Colombia
- Cote D'ivoire
- Croatia (Hrvatska)
- Cuba
- Czech Republic
- Denmark
- Dominican Republic
- Ecuador
- Egypt
- Estonia
- Finland
- France
- Georgia
- Germany
- Ghana
- Hong Kong
- Hungary
- Iceland
- India
- Indonesia
- Iran
- Ireland
- Israel
- Italy
- Jamaica
- Jordan
- Kazakhstan
- Kenya
- Kuwait
- Latvia
- Lebanon
- Libya
- Lithuania
- Luxembourg
- Macedonia
- Malawi
- Malaysia
- Malta
- Mauritius
- Mexico
- Morocco
- Namibia
- Nepal
- Netherlands
- New Zealand
- Nigeria
- Norway
- Oman
- Pakistan
- Paraguay
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Romania
- Russian Federation
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sri Lanka
- Sudan
- Sweden
- Switzerland
- Tanzania
- Thailand
- Trinidad & Tobago
- Tunisia
- Turkey
- Uganda
- Ukraine
- United Arab Emirates
- United Kingdom
- United States
- Uruguay
- Uzbekistan
- Venezuela
- Vietnam
- Zambia
- Zimbabwe
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment